he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信道地址
- 2022-04-202013年国际抗癫痫总会抗癫痫药使用指南
- 2022-04-13美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- 2022-04-12UCB的Vimpat癫痫新适应症在美国获批
- 2022-04-11GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 2022-04-11控制癫痫患者再次抽搐,不包括可选药物?
- 2022-04-072016AAN:神经专家发表了有前途的专业见解
- UCB的Vimpat癫痫新适应症在美国获批
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 控制癫痫患者再次抽搐,不包括可选药物?
- 2016AAN:神经专家发表了有前途的专业见解
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 癫痫治疗障碍仍难以克服
- 综述:癫痫持续状态诊治最新进展
- 抗癫痫药物预防新发癫痫:任重而道远
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 月经性癫痫患者妊娠期癫痫控制更好
- 如何使用难治性癫痫持续状态剂?
- 泡温泉时不能忽视的事情
- 心理百科:春节期间小心疾病
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 上海率先探索异地就医门诊费直接结算
- 癫痫患者在治疗时应注意什么?
- JAMA Neurology:左乙拉西坦对阿尔茨海默病患者的认知功能有影响,不伴有癫痫活动
- 癫痫患者手术评估新型工具
- 不注意这些问题,吃多少药都没用!
- 癫痫的治疗方法 中医拔罐治疗癫痫的小方法(2)
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 心率多少正常 如何保持正常心率不变
- 特发性癫痫大发作药物治疗的首选
- 第一批国家级 癫痫中心单位获得认证并授权
- 预测癫痫患者再入院风险
- FDA批准Aptiom用于治疗患者癫痫发作
- 怎样鉴别癫痫病的早期征兆
- 20131029养生堂:王文志讲心脑血管结核病的预防
- 女性癫痫病怎么病人最快
- 癫痫病应如何用药?
- 癫痫疾病的检查诊断方法有哪些 癫痫疾病的检查服务费高吗
- 脑瘤的治疗方法 中医拔罐治脑瘤小方法(2)
- 睡觉时抽搐到底癫痫病?
- 阿尔茨海默病或是人类特有疾病,同神经元及神经环路活性诱发相关
- 引致癫痫病发作的因素有哪些
- 乙肝疫苗多久打一次 有哪些须知
- 得了妇科病,害怕影响不孕?摆脱它,这些正确观念你要有!
- 华南地区女性癫痫病治疗
- 癫痫病诊断的依据是什么